Boardwave’s Post

#ICYMI: MedTech Strategist/Market Pathways's own Stephen Levin will be moderating the "Successfully Navigating Exits and Financings in Tough Times" panel discussion between Earlybird Venture Capital's Dr. Christoph Massner and LimFlow SA's Dan Rose at MedTech Europe's The MedTech Forum 2024 on Thursday, May 23 at 10:40AM-11:30AM. Despite a challenging environment for M&A and fundraising amidst an evolving EU regulatory landscape, this panel features strategics, investors and start-up CEOs who are doing deals in spite of these obstacles, and are here to share their strategies in achieving these goals. Lean more here: https://lnkd.in/ex3Y9ySx #MTF2024 #conferences #paneldiscussion #medtech #medtechindustry #medtechinnovation #regulatory

𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐫𝐞𝐚𝐝 𝐒𝐈𝐄 𝐕𝐞𝐧𝐭𝐮𝐫𝐞𝐬 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐅𝐞𝐦𝐭𝐞𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 28 pages later and here are some key points that jumped out to me! 🌟 The Femtech sector as a whole, is projected to be worth over $𝟔𝟎𝐁𝐧 by 2027. 🌟 Leading regions in Europe for Femtech include the UK (31.8%), France (18.3%), Germany (12%), Sweden (7.9%) and Switzerland (5.5%). 🌟 Female founded Femtech start-ups raised $4.6M compared to $9.2M by those with all-male teams on average. 🌟 Investment in Women's Health has grown with deal counts up by 314% since 2018. 🌟 𝐎𝐧𝐥𝐲 𝟒% of all healthcare R&D is targeted at Women's Health issues specifically (🙄 *big sigh*). 🌟 Investing $300 million in women's health research = $𝟏𝟑 𝐁𝐈𝐋𝐋𝐈𝐎𝐍 for the US economy in the next 13-25 years. 🌟 𝐎𝐧𝐥𝐲 𝟏𝟓% of EU VC General Partners are women!! Worth a read to all my Femtech connections! If you have read it, what was most interesting to you? #femtech #vcfunding #sieventures Read the whole report here: https://lnkd.in/e4diNmEJ

Tamtron listed at the end of 2022 on the Nasdaq Helsinki First North Growth Market, during a period when the IPO market had slowed down and valuation levels were dropping. Despite these challenges, Tamtron’s impressive 50-year journey of continuous development convinced investors, leading to a successful listing. 📈 Since then, Tamtron Group Oyj has delivered on its promises, driving significant growth through strategic acquisitions. These moves have expanded Tamtron’s operations and strengthened its position in international markets. Today, Tamtron operates in 9 countries, with partners in an additional 60. Tamtron’s growth is built on a foundation of sustainable business practices and innovation, propelling the company toward even greater global success. The future looks bright as Tamtron continues to execute its strategy with confidence. 🌍 From a customer perspective, Tamtron’s AI-powered weighing solutions provide the accuracy and efficiency needed for demanding applications. For many customers, their entire business depends on accurate weighing -incoming goods are weighed and paid for based on that data, while outgoing goods are weighed for invoicing purposes. By leveraging SaaS and AI technologies, Tamtron delivers real-time data collection, analysis, and predictive maintenance -enhancing operational efficiency, reducing downtime, and optimizing resource use. 💡 These solutions not only improve decision-making and cut costs but also help customers meet their sustainability goals by minimizing environmental impacts. Partnering with Tamtron offers a competitive edge in an ever-evolving market, enabling both growth and long-term success. 🚀 #Tamtron #Material #Flow #Management #Growth #Innovation #AI #SaaS #Sustainability #WeighingSolutions #Technology #InternationalBusiness #Nasdaq #Listed

One day until DeviceTalks in Boston! I'm excited for tomorrow's panel on "How IP Can Drive Funding & Exits" moderated by David Dykeman from Greenberg Traurig, LLP. Here is what to expect: Join medtech VCs and CEOs as they delve into strategies for positioning your medtech company to attract investors, collaborators, and acquirers. Intellectual Property (IP) is critical for medtech companies to attract funding, strategic partners, and navigate an exit through M&A or IPO. To become attractive funding or M&A targets, medtech companies must prioritize de-risking and aligning their commercial, regulatory, and IP strategies. Gain insights into best practices and pitfalls to avoid when building strategic patent portfolios to close funding, stay competitive, and secure a successful exit. See you there! #DeviceTalksBoston #MedTech #IPstrategy

In case you missed it, I discuss the best performing IPO of the year BlinkLab Limited I also mention Echo IQ (ASX:EIQ) and Vinyl Group Thanks for having me on ausbiz Note that we have an interest in VNL. $BB1 $EIQ $VNL #IPO #ASX #ausbiz #tradingday

Innventure lists on Nasdaq today, marking a significant milestone in our mission to unlock value from breakthrough technology solutions. This event celebrates our journey in building operating companies we believe have the potential to achieve billion-dollar enterprise value. Our listing on Nasdaq reflects our commitment to revolutionizing how innovation comes to life. As we join Nasdaq, we acknowledge the collective efforts that have brought us to this point. Our focus remains on our core mission: creating companies to transform tomorrow. Today's listing opens a new chapter for Innventure. We're excited to continue bridging the innovation gap, turning R&D into ROI, and changing the game in how breakthrough technologies find their path to market. Discover more: https://bit.ly/3XScJYp #InnventurexNasdaq #NasdaqListing #innventuregoespublic #NasdaqListed

Revisiting an outstanding 2023, #LSIAlumni raised more than $1.67 Billion in capital and closed 11 M&A transactions across 117+ total deals. Our new spreadsheet indexes these transactions, investors involved (publicly disclosed), and links to our proprietary media and coverage of the companies themselves. 🔗 Click here to see the 2023 LSI Alumni Funding Report: https://lnkd.in/gzSb_tKX We’ve received great feedback on this report from founders, VCs, strategics, and many other executives in Medtech and Healthtech, and look forward to publishing more resources on the news and stories of our growing global community. You’ll also see many of the alumni featured on this report at #LSIUSA24 this March. We’re less than 7 weeks away and have selected over 300 of the most exciting emerging companies in the industry to present to a full house of investors and strategics. Click the link above to see 117+ LSI Alumni deals from 2023.

On May 8, 2024, LegalOne, a legal rankings organization, announced its "Deals of the Year 2023", which highlights 11 Han Kun-advised deals that topped the list. The highlighted deals are (in the order of their rankings): • Beisen Holding, Chinese HR SaaS company, completes IPO in Hong Kong • Cheche Technology completes Nasdaq listing through de-SPAC transaction • Gala Technology's IPO on the Hong Kong Stock Exchange • HighTide Therapeutics' IPO and listing on Hong Kong Stock Exchange • J&T Express completes Hong Kong IPO with a WVR structure • Kidswant Children Products completes RMB 1.039 billion convertible bond issuance • MLOPTIC finalizes IPO and listing on Shanghai Stock Exchange's STAR Market • NIO completes USD 1 billion convertible senior notes offering • Seacon Shipping Group completes IPO and listing on Hong Kong Stock Exchange • Star Plus Legend's IPO and listing on Hong Kong Stock Exchange • ZKH Group's IPO and listing on New York Stock Exchange

Top 10 Seattle-area tech companies likely to go public: GeekWire reports on the status of Seattle's tech industry, highlighting a two-year IPO drought in the region. The recent stock market rise and positive trends in the tech sector could lead to more IPOs this year. PitchBook identifies the top 10 Seattle-area tech companies likely to go public: Outreach Tanium Rad Power Bikes TerraPower TwinStrand Biosciences Highspot Qumulo Viome Life Sciences Shape Therapeutics OfferUp Are you a B2B SaaS company with $3-$20M ARR and considering selling? Please reach out to me directly, and let's talk about it.

🚀 How’s the European tech market faring as we head into Q4? Nenad Marovac cast an eye over the state of the market for the foreword of Tech.eu’s September monthly report – highlighting a threefold increase in investment compared with August, with €4.2 billion raised across 347 deals. Between this and the sense of growing confidence among the investors and operators at our Portfolio Day in Berlin last month, Nenad makes the case for a strong Q4 in Europe’s tech and VC ecosystem. Read the full report for more: https://lnkd.in/e3BGTaPQ    #DNCapital #VC